Evidence map›Paper›PMID 33465050›Full record

ArticleAging2021

Fighting the storm: could novel anti-TNFα and anti-IL-6

Anna Kovalchuk, Bo Wang, Dongping Li, Rocio Rodriguez-Juarez, Slava Ilnytskyy, Igor Kovalchuk, Olga Kovalchuk

Open access · hybridAbstract read
In one paragraph

Article in Aging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 37 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Substances of abuse and their effect on SAR-CoV-2 pathogenesis.NeuroImmune pharmacology and therapeutics · 2023
    Review
  5. Article
  6. Article
  7. The Anti-Inflammatory Effects ofMolecules (Basel, Switzerland) · 2023
    Article
  8. Review
  9. Cannabinoids as Emergent Therapy Against COVID-19.Cannabis and cannabinoid research · 2022
    Review
  10. Article
  11. Glycyrrhetinic acid: A potential drug for the treatment of COVID-19 cytokine storm.Phytomedicine : international journal of phytotherapy and phytopharmacology · 2022
    Article
  12. Article
  13. Article
  14. Article
  15. Cannabidiol and SARS-CoV-2 Infection.Frontiers in immunology · 2022
    Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Cannabinoids for SARS-CoV-2 and is there evidence of their therapeutic efficacy?Turkish journal of biology = Turk biyoloji dergisi · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Anna KovalchukPathway Research Inc., Lethbridge, AB T1K7X8, Canada.
Bo WangPathway Research Inc., Lethbridge, AB T1K7X8, Canada.
Dongping LiPathway Research Inc., Lethbridge, AB T1K7X8, Canada.
Rocio Rodriguez-JuarezPathway Research Inc., Lethbridge, AB T1K7X8, Canada.
Slava IlnytskyyPathway Research Inc., Lethbridge, AB T1K7X8, Canada.
Igor KovalchukPathway Research Inc., Lethbridge, AB T1K7X8, Canada.
Olga KovalchukPathway Research Inc., Lethbridge, AB T1K7X8, Canada.
University of Lethbridge · CAUniversity of Calgary · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The main aspects of severe COVID-19 disease pathogenesis include hyper-induction of proinflammatory cytokines, also known as 'cytokine storm', that precedes acute respiratory distress syndrome (ARDS) and often leads to death. COVID-19 patients often suffer from lung fibrosis, a serious and untreatable condition. There remains no effective treatment for these complications. Out of all cytokines, TNFα and IL-6 play crucial roles in cytokine storm pathogenesis and are likely responsible for the escalation in disease severity. These cytokines also partake in the molecular pathogenesis of fibrosis. Therefore, new approaches are urgently needed, that can efficiently and swiftly downregulate TNFα, IL-6, and the inflammatory cytokine cascade, in order to curb inflammation and prevent fibrosis, and lead to disease remission.

Indexed as

CannabisCOVID-19Cytokine Release SyndromeInterleukin-6 InhibitorsAnti-Inflammatory AgentsCannabinoidsCell LineFibroblastsHumansInflammationInterleukin-6Plant ExtractsSARS-CoV-2SkinTissue Culture TechniquesTumor Necrosis Factor-alphaAnti-Inflammatory AgentsCannabinoidsIL6 protein, humanInterleukin-6Interleukin-6 InhibitorsPlant ExtractsTNF protein, humanTumor Necrosis Factor-alphaCOVID-19cytokine stormfibrosisIL-6medical cannabisSARS-CoV2TNFα

Identifiers

PMID33465050
PMCPMC7880317
OpenAlexW3125919088

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.